Hostname: page-component-78c5997874-94fs2 Total loading time: 0 Render date: 2024-11-10T13:37:01.550Z Has data issue: false hasContentIssue false
  • English
  • Français

Effectiviness and safety of antidepresants in bipolar depression

Published online by Cambridge University Press:  01 September 2022

T. Jupe  and
B. Zenelaj
T. Jupe*
Affiliation:
Psychiatric Hospital of Attica, 5th Acute Psychiatric Department, Chaidari, Greece
B. Zenelaj
Affiliation:
National Center for Children Treatment and Rehabilitationn, Child Psychiatry, Tirana, Albania
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Depressive episodes are associated with higher morbidity, mortality (mostly suicidality. Despite the high prevalence and the devastating impact of this condition, there is a long‐standing debate about its treatment, particularly about the use of antidepressants. International guidelines and expert consensus recommend to avoid AD for bipolar depression, or to use AD with caution and as second line treatment only if the depressive episode shows poor response to mood stabilizers (MS) and to some second generation antipsychotics (SGA) (cariprazine, lurasidone, quetiapine and olanzapine combined with fluoxetine) in monotherapy and in combination. Contrary to the advice of guidelines and experts, 50%–80% of acute bipolar depressive episodes are treated with AD in everyday clinical practice.

Objectives

To evaluate the effectiveness and the safety of AD acute treatment in patients with bipolar depression

Methods

Literature review (PubMed)

Results

Short‐term safety, switching and suicidality did not differ significantly, and no suicide attempt was observed. Concerning long‐term safety, patients with bipolar depression had a significant reduction of depressive and total recurrences during the first year.

Conclusions

Acute AD treatment of bipolar depression is effective in the short term and safe in the short‐ and long‐term

Disclosure

No significant relationships.

Keywords

Antidepressantsbipolar depression
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S718
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.